In a bold move, the AIDS Healthcare Foundation (AHF) has issued a warning in a recent Lancet HIV letter, claiming that the World Health Organization's (WHO) recommended three-test system for HIV diagnosis might inadvertently hinder timely access to treatment. This revelation is particularly concerning as it could impact the lives of countless individuals awaiting life-saving HIV care.
The WHO's three-test strategy aims to minimize false-positive results, but AHF argues that it may create unintended consequences. Many clinics, especially those in resource-limited settings, struggle to conduct three separate rapid tests during a single visit due to staffing, supply, and time constraints. This challenge is further exacerbated in countries like Kenya, where AHF teams report longer wait times and delays in starting antiretroviral therapy (ART).
Here's where it gets controversial: AHF suggests that the rarity of false positives when using two high-quality rapid tests correctly already provides sufficient accuracy. So, is the third test really necessary in most cases? This question sparks debate, especially when considering the potential harm caused by treatment delays.
AHF proposes an alternative approach already implemented in countries like Brazil: initiating treatment after two positive rapid tests and simultaneously sending a blood sample for a confirmatory viral load test. If the latter reveals a negative result, treatment can be safely discontinued. This method ensures accuracy while preventing delays that could compromise patients' health.
The letter urges countries to adapt their HIV testing policies to local circumstances. Advanced verification tools, such as viral load testing, rapid molecular options, or fourth-generation assays, can maintain accuracy without delaying treatment, particularly in busy or resource-constrained clinics.
This correspondence, authored by Dr. Adele Benzaken, Dr. Fernanda Fonseca, Dr. Penninah Iutung, Dr. Marcus Lacerda, and Michael Weinstein of AHF, highlights the importance of balancing accuracy and accessibility in HIV testing. It invites readers to consider the potential benefits of alternative testing strategies and encourages discussion on how to best serve those affected by HIV/AIDS.
To learn more about AHF's global efforts, visit their website, Facebook, Twitter, or Instagram. The full text of the letter is also available online, offering a deeper dive into this critical healthcare issue.
